NFKB1 and nasopharyngeal carcinoma: In addition to CYLD, another major negative regulator of NF-κB, namely TRAF3 (TNF receptor associated factor 3), was also found to be aberrant in as high as 17.5% of microdissected EBV(+) NPC tumors [43].